Nucleic Acid Based Drug Delivery

Nucleic acids science and technologies experience tremendous progress and changes. The conference will feature prominent experts discussing latest advances in nucleic acids research and development: TNA for treating cancer and viral diseases in the near future for Drug Delivery includes Novel RNAi-Based Therapy, advances in siRNA delivery, oligonucleotide drug delivery, viral gene therapy and Artificial microRNAs, non-coding RNA (miRNA, piRNA, lncRNA, and lincRNA) this architect session to play an important role in the fields of cancer targeting and pharmaceutical nanotechnology.

The RNAi nucleic acid drug delivery market was worth $169.1 million globally in 2012 and by 2017 it is estimated the market will have matured. By 2017, the market for RNAi drug delivery could be around $1.1 billion globally, reflecting a compound annual growth rate (CAGR) of 45%.

  • Novel RNAi-Based Therapy
  • Viral gene therapy
  • Aptamer and Antisense
  • Cancer-targeted siRNA delivery
  • Drug target miRNAs
  • MicroRNA Technology
  • Importing from DNA Nanotechnology
  • Formulation strategy for siRNA delivery
  • Oligonucleotide Drug Delivery
  • Nanotechnologies Relevant to RNA Research
  • Strategies for siRNA delivery
  • Nanoimmuology and RNA Nanotechnology
  • Extracellular RNA for Biomarker Development

Related Conference of Nucleic Acid Based Drug Delivery

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Nucleic Acid Based Drug Delivery Conference Speakers

Recommended Sessions

Related Journals

Are you interested in